Lipid paradox in rheumatoid arthritis: the impact of serum lipid measures and systemic inflammation on the risk of cardiovascular disease - Wikidata - awgldk - TriplyDB

Lipid paradox in rheumatoid arthritis: the impact of serum lipid measures and systemic inflammation on the risk of cardiovascular disease

Lipid paradox in rheumatoid arthritis: the impact of serum lipid measures and systemic inflammation on the risk of cardiovascular disease

http://www.wikidata.org/entity/Q34684331

about

Biologics, cardiovascular effects and cancer Cardiovascular risk assessment in rheumatoid arthritis - controversies and the new approach Cardiovascular risk in rheumatoid arthritis: assessment, management and next steps Cardiovascular comorbidity in rheumatic diseases: a focus on heart failure Managing cardiovascular risk in patients with inflammatory arthritis: practical considerations Cardiovascular disease risk scores in the current practice: which to use in rheumatoid arthritis?Residual Cardiovascular Risk in Chronic Kidney Disease: Role of High-density Lipoprotein Association of rheumatoid arthritis susceptibility gene with lipid profiles in patients with rheumatoid arthritis Association of hyperlipidaemia, inflammation and serological status and coronary heart disease among patients with rheumatoid arthritis: data from the National Veterans Health Administration Differential associations of inflammatory and endothelial biomarkers with disease activity in rheumatoid arthritis of short duration Imaging atherosclerosis in rheumatoid arthritis: evidence for increased prevalence, altered phenotype and a link between systemic and localised plaque inflammation.Myocardial Perfusion in Rheumatoid Arthritis Patients: Associations with Traditional Risk Factors and Novel Biomarkers.Concomitant Use of Statins in Tocilizumab-Treated Patients with Rheumatoid Arthritis: A Post Hoc Analysis.HDL cholesterol efflux capacity in rheumatoid arthritis patients: contributing factors and relationship with subclinical atherosclerosis.Lipid and lipoprotein levels and trend in rheumatoid arthritis compared to the general population.Elevated interleukin-10: a new cause of dyslipidemia leading to severe HDL deficiency Cardiovascular involvement in autoimmune diseases.What effect is really being measured? An alternative explanation of paradoxical phenomena in studies of osteoarthritis progression.Cardiovascular risk in rheumatoid arthritis: recent advances in the understanding of the pivotal role of inflammation, risk predictors and the impact of treatment Selection bias in rheumatic disease research.LDL cholesterolemia as a novel risk factor for radiographic progression of rheumatoid arthritis: a single-center prospective study Utility of different cardiovascular disease prediction models in rheumatoid arthritis.What is the future of targeted therapy in rheumatology: biologics or small molecules?The association between reduction in inflammation and changes in lipoprotein levels and HDL cholesterol efflux capacity in rheumatoid arthritis.EULAR task force recommendations on annual cardiovascular risk assessment for patients with rheumatoid arthritis: an audit of the success of implementation in a rheumatology outpatient clinic.Significant effects of biologic therapy on lipid profiles and insulin resistance in patients with rheumatoid arthritis.Association between lipid levels and major adverse cardiovascular events in rheumatoid arthritis compared to non-rheumatoid arthritis patients.On the HUNT for cardiovascular risk factors and disease in patients with psoriatic arthritis: population-based data from the Nord-Trøndelag Health Study.Disease activity in rheumatoid arthritis and the risk of cardiovascular events.Methotrexate, Cyclosporine A, and Biologics Protect against Atherosclerosis in Rheumatoid Arthritis.Hyperlipidemia in rheumatoid arthritis patients in Saudi Arabia. Correlation with C-reactive protein levels and disease activity.The role of rheumatoid arthritis (RA) flare and cumulative burden of RA severity in the risk of cardiovascular disease.Usefulness of risk scores to estimate the risk of cardiovascular disease in patients with rheumatoid arthritis.Dyslipidemia and changes in lipid profiles associated with rheumatoid arthritis and initiation of anti-tumor necrosis factor therapy An integrated biochemical prediction model of all-cause mortality in patients undergoing lower extremity bypass surgery for advanced peripheral artery disease.High serum cholesterol predicts rheumatoid arthritis in women, but not in men: a prospective study.Cardiovascular disease and rheumatoid arthritis: an update.Association of vitamin D with cardiometabolic risk factors in rheumatoid arthritis Challenges of developing a cardiovascular risk calculator for patients with rheumatoid arthritis.Traditional cardiovascular risk factors, inflammation and cardiovascular risk in rheumatoid arthritis.

P2860

Q24568196-BE8BE772-3165-4247-8474-0B8481C16763 Q26738461-CAAC4BF4-8E51-469F-B845-71737E9CE16B Q26744334-19740652-A712-4DF0-B711-CBEE8838FE16 Q26823443-8EF8F9FF-2377-44EB-997C-1AF51F769FA2 Q27694518-7F73E689-6F3C-4087-AF31-E420668FE70D Q28082992-9A0E187B-C4CC-4278-B33B-E1D0F6DF5A2C Q28083619-1913E276-0B51-4EDA-864A-5AC332F511A4 Q28386085-18A19DD1-477A-4BD2-BBD1-77A2E6AC8E68 Q30885473-7CE957AC-0F4A-42C2-A0AA-D4D14D0762C3 Q33593925-292BFB2E-D163-4957-B6CC-4F9756886863 Q33678290-8BB834BA-D34F-486D-87FF-5E5EB1AF8F3A Q33695937-8E6C644F-668C-4303-BA10-47D0668904B6 Q33725505-82D363EB-1EF6-439A-A534-DA10A28276B1 Q33750044-FDCD2372-E354-4A9C-B8A5-8EE2DF159100 Q33765761-5F272816-8AD6-43C8-8200-59E788352041 Q33910884-41B6299F-3122-46F9-ABF0-2CBB67338855 Q34081242-D5D5BD68-0CE7-41A7-BCDF-0D3E769A8A17 Q34383621-37759714-06DD-49BA-8BD9-FB93184AE3A0 Q34563216-2F29D830-17A3-4648-B8E4-5608794F1D44 Q34662693-AC0CCD2D-3BB9-46F2-88DE-C2F011B3D718 Q34901953-9E5B97E0-6C0B-4BB1-B081-C0FC8F10C864 Q35045933-915D2809-13AE-4545-87C0-AB2797AEF841 Q35118364-6478D7F6-F976-434B-A2A2-795CECA9AEBA Q35135726-4D5FB9DE-F653-4D59-92AE-019977EF1314 Q35177998-2FFC4EA3-56C1-4802-ACE9-8B6A3CBB7F4F Q35257568-6A9AE4BE-8354-4F98-97CC-F78AAFAA82B6 Q35564852-A74D3447-600B-4F9C-B3CC-6C1FB8DECE03 Q35588201-0C5E4373-5C19-4BA9-8E5E-0101F4A52F31 Q35655764-5800CCC9-D286-4A56-B9BE-2140689AB1A1 Q35673987-9ABD818E-00A4-4C3E-8E0A-A656FEFA5486 Q35681167-DCE239A4-2067-4B09-AE21-87619214E76B Q35904678-06601084-D713-47D5-8659-BE34E815CD68 Q36098818-A1A67768-5B35-451E-9804-53279C6BC6A1 Q36113215-4CF69EF9-6A38-4A1F-B615-54A80DF4927C Q36146980-F9BB27F6-F60A-43E5-9C30-C6091ABE58BD Q36155818-A126BA4C-0854-41BA-A25E-9FBDCC033FAD Q36218375-C36AB5AF-1371-4D7D-AA2F-A1155DF3340D Q36291358-232639D9-5346-4CEC-B8CA-10FF789C7C93 Q36320021-03B1423F-3F64-4451-9C6B-92907F355357 Q36464352-8D8B3DDC-83B7-48F7-8267-3A2797DE352D

P2860

Lipid paradox in rheumatoid arthritis: the impact of serum lipid measures and systemic inflammation on the risk of cardiovascular disease

http://www.wikidata.org/entity/Q34684331

description

2011 nî lūn-bûn

@nan

2011 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Lipid paradox in rheumatoid ar ...... risk of cardiovascular disease

@ast

Lipid paradox in rheumatoid ar ...... risk of cardiovascular disease

@en

Lipid paradox in rheumatoid ar ...... risk of cardiovascular disease

@nl

type

label

Lipid paradox in rheumatoid ar ...... risk of cardiovascular disease

@ast

Lipid paradox in rheumatoid ar ...... risk of cardiovascular disease

@en

Lipid paradox in rheumatoid ar ...... risk of cardiovascular disease

@nl

prefLabel

Lipid paradox in rheumatoid ar ...... risk of cardiovascular disease

@ast

Lipid paradox in rheumatoid ar ...... risk of cardiovascular disease

@en

Lipid paradox in rheumatoid ar ...... risk of cardiovascular disease

@nl

P1433

Q34684331-51B8E125-8E48-4BBF-9BA6-8419559EB0C7

P1476

Q34684331-2C65DADC-BFDB-42F2-AB19-E5FE12F50476

P2093

Q34684331-47B7CBD0-C357-4621-A600-594CAE9A0372

Q34684331-64679356-3EA7-47D3-99E2-78488C889BBF

Q34684331-66FA5412-1B45-4AEE-B2CE-25D2BA5B5648

Q34684331-9F3EEF37-CE05-4631-B312-40810F9F4C6C

Q34684331-CFD0043D-2F07-429A-A1C4-D7AEE851DEDC

Q34684331-E8419241-88CB-48C9-A273-1D379B82DB38

Q34684331-FE6139A5-9BF5-4E54-894C-354BC7A9C392

P2860

Q34684331-06E4B082-55B7-47F5-A059-6AE4B11094FD

Q34684331-0A0FE973-7298-4719-A4D3-152D4C2B8903

Q34684331-1070FB81-272A-4403-AEF7-D96AE622759B

Q34684331-15A118B5-5788-4E12-B1D5-84D0D88B4AD8

Q34684331-1744167A-2EED-4A5F-B6DA-6D6C6083D2A8

Q34684331-27F4F3F7-FF77-4EB3-A982-6707A737BAF2

Q34684331-356296C9-32A0-44D5-BD71-75E7941C750D

Q34684331-427A23E2-F7E6-4D0A-ACE8-8571972E9396

Q34684331-43008688-DDBF-44ED-89D5-BF0A3B40A9D1

Q34684331-4488B453-9E6F-4E78-9469-93CAB527C006

P304

Q34684331-A234E353-0277-4D16-84DC-CC845BB6ECB3

P31

Q34684331-50B4E8AC-F5A8-48C8-90A7-CFA4F86CD772

P356

Q34684331-1FFDD80E-A278-4197-A2BB-C9CE90DE9BC1

P407

Q34684331-1D6D099E-BC5B-451C-89C5-0C65AECA3BF3

P433

Q34684331-997AEA8E-3EA8-4A7E-9A6A-C1D04E9462BA

P478

Q34684331-43AB0CBB-C0B5-4A9E-84AA-3C35F27CCBFF

P577

Q34684331-8CF8C510-AF9C-426E-9A8A-A05E82E87D4A

P5875

Q34684331-30BABC54-78CE-4EF5-B74E-A69F137A0939

P698

Q34684331-1F158B72-99E3-43F5-9778-8B47C26C7BA2

P921

Q34684331-3CFB710E-300B-4511-BB0E-4DA42D9D46CC

P932

Q34684331-C7A5F744-3541-4EBA-A7C0-C4FB6F4C782C

P356

ARD.2010.135871

P1433

Annals of the Rheumatic Diseases

P1476

Lipid paradox in rheumatoid ar ...... risk of cardiovascular disease

@en

P2093

Cynthia S Crowson

http://www.w3.org/2001/XMLSchema#string

Elena Myasoedova

http://www.w3.org/2001/XMLSchema#string

Hilal Maradit Kremers

http://www.w3.org/2001/XMLSchema#string

Patrick D Fitz-Gibbon

http://www.w3.org/2001/XMLSchema#string

Sherine E Gabriel

http://www.w3.org/2001/XMLSchema#string

Terry M Therneau

http://www.w3.org/2001/XMLSchema#string

Veronique L Roger

http://www.w3.org/2001/XMLSchema#string

P2860

The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report

Cholesterol and all-cause mortality in elderly people from the Honolulu Heart Program: a cohort study

Acute-phase proteins and other systemic responses to inflammation

Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein

Levels of C-reactive protein associated with high and very high cardiovascular risk are prevalent in patients with rheumatoid arthritis.

Why do people with rheumatoid arthritis still die prematurely?

Human very low density lipoproteins and chylomicrons can protect against endotoxin-induced death in mice

The patient record in epidemiology.

P304

482-487

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/ARD.2010.135871

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

70

http://www.w3.org/2001/XMLSchema#string

P577

2011-01-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

49738863

http://www.w3.org/2001/XMLSchema#string

P698

21216812

http://www.w3.org/2001/XMLSchema#string

P921

cardiovascular disease

P932

3058921

http://www.w3.org/2001/XMLSchema#string